Profile
| Metric | Value |
|---|---|
| Full Name | AstraZeneca PLC |
| Ticker | NASDAQ: AZN |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | General Drug Manufacturers |
| Country | United Kingdom |
| IPO | |
| Indexes | |
| Website | astrazeneca.com |
| Employees | 94,300 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $91.22 | |
| Price, 1D Change | -0.38% | |
| Market Cap | $283B | |
| TTM Dividend Yield | 1.72% | |
| PE Ratio | 30.29 | |
| Beta | 0.39 | |
| Revenue | $54B | |
| Revenue, 1Y Change | +18.08% | |
| EPS | $2.25 | |
| EPS, 1Y Change | +18.11% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | $0.52 | |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 2:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $2.25 | |
| EPS Estimate | $4.59 | |
| EPS Est. Change | +104.01% | |
| Revenue | $54.10B | |
| Revenue Estimate | $58.63B | |
| Revenue Est. Change | +8.39% | |
| Current Price | $91.22 | |
| Price Target | - | $103.00 |
| Price Tgt. Change | - | +12.91% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $3.70 | $1.91 | -48.48% | |
| $4.13 | $2.25 | -45.42% | |
| $4.59 | N/A | +104.01% | |
| $5.15 | N/A | +128.74% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $45.87B | $45.81B | -0.14% | |
| $53.36B | $54.10B | +1.39% | |
| $58.63B | N/A | +8.39% | |
| $62.34B | N/A | +15.24% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +36.48% | |
| Price, 3Y | +28.84% | |
| Market Cap, 1Y | +36.49% | |
| Market Cap, 3Y | +28.88% | |
| Revenue, 1Y | +18.08% | |
| Revenue, 3Y | +42.99% | |
| EPS, 1Y | +18.11% | |
| EPS, 3Y | +5,643.37% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $91.22 | |
| SMA 200 | $77.87 | |
| SMA 200 vs Price | -14.63% | |
| SMA 50 | $88.84 | |
| SMA 50 vs Price | -2.61% | |
| Beta | 0.39 | |
| ATR | $1.29 | |
| 14-Day RSI | 52.21 | |
| 10-Day Volatility | 8.05% | |
| 1-Year Volatility | 25.39% |
Dividends
| Metric | Date | Value |
|---|---|---|
| Last Paid | $0.52 | |
| Upcoming | N/A | N/A |
| Dividend Yield | 1.63% | |
| Total Dividend | $1.49 | |
| Dividends Paid | $4.63B | |
| Payout Ratio | 65.74% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $54.10B | |
| EPS | $2.25 | |
| Gross Profit | $40.56B | |
| Gross Margin | 74.98% | |
| Operating Profit | $10.00B | |
| Operating Margin | 18.50% | |
| Net Income | $7.04B | |
| Net Margin | 13.01% | |
| EBITDA | $17.12B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.71 | |
| Current Ratio | 0.93 | |
| Quick Ratio | 0.74 | |
| - | ||
| F-Score | 8 | |
| Altman Z-Score | 3.56 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 30.29 | |
| PS Ratio | 4.87 | |
| PB Ratio | 6.16 | |
| EV/EBITDA | 15.96 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $40.79B | |
| Cash & Equivalents | $5.49B | |
| Total Assets | $104.04B | |
| Current Assets | $25.83B | |
| Total Liabilities | $63.16B | |
| Current Liabilities | $27.87B | |
| Total Debt | $30.30B | |
| Short Term Debt | $2.68B | |
| Accounts Payable | $3.64B |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $44.07B | |
| Operating Expenses | $33.86B | |
| Cost Of Goods Sold | $13.53B | |
| SG&A | $20.53B | |
| D&A | $6.69B | |
| Interest Expense | $0.00 | |
| Income Tax | $1.65B |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $11.86B | |
| CFI | -$7.98B | |
| CFF | -$4.00B | |
| Capex | $4.59B | |
| Free Cash Flow | $7.28B |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| UBS | → | |
| UBS | → | |
| Erste Group | → | |
| TD Cowen | → | |
| Goldman Sachs | ||
| Argus Research | → | |
| BMO Capital | → | |
| Deutsche Bank | → | |
| BMO Capital | → | |
| Deutsche Bank | → |
Analyst sentiment
Institutional ownership
Screeners with AZN
Data Sources & References
- AZN Official Website www.astrazeneca.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/901832/000165495425012630/0001654954-25-012630-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm
- List of NASDAQ 100 Companies www.nasdaq.com/market-activity/quotes/nasdaq-ndx-index
- AZN Profile on Yahoo Finance finance.yahoo.com/quote/AZN
- AZN Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/azn
FAQ
What is the ticker symbol for AstraZeneca PLC?
The ticker symbol for AstraZeneca PLC is NASDAQ:AZN
Does AstraZeneca PLC pay dividends?
Yes, AstraZeneca PLC pays dividends. The last payment was $0.52, with an ex-dividend date on August 8, 2025
What sector is AstraZeneca PLC in?
AstraZeneca PLC is in the Healthcare sector
What industry is AstraZeneca PLC in?
AstraZeneca PLC is in the General Drug Manufacturers industry
What country is AstraZeneca PLC based in?
AstraZeneca PLC is headquartered in United Kingdom
When did AstraZeneca PLC go public?
AstraZeneca PLC initial public offering (IPO) was on May 12, 1993
Is AstraZeneca PLC in the S&P 500?
No, AstraZeneca PLC is not included in the S&P 500 index
Is AstraZeneca PLC in the NASDAQ 100?
Yes, AstraZeneca PLC is included in the NASDAQ 100 index
Is AstraZeneca PLC in the Dow Jones?
No, AstraZeneca PLC is not included in the Dow Jones index
When was AstraZeneca PLC last earnings report?
AstraZeneca PLC's most recent earnings report was on November 6, 2025
When does AstraZeneca PLC report earnings?
The next expected earnings date for AstraZeneca PLC is February 10, 2026